Pfizer Advancing Once-Daily Danuglipron For Obesity

 
• By Jessica Merrill

A modified-release formulation of the oral GLP-1 has been selected for development, Pfizer said. Dose-optimization studies will begin in the second half of the year.

Pfizer
Pfizer updated investors on the development of danuglipron • Source: Shutterstock

More from Alimentary/Metabolic

More from Therapy Areas